Clinical Trial Update: Non Small Cell Lung Cancer Patients Treated With Erlotinib Six Months or Longer

View source ↗

Summary

The update reports outcomes for non-small cell lung cancer patients who received erlotinib for six months or longer in a completed study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Non Small Cell Lung Cancer | Status: COMPLETED